Development of synthetic lethality anticancer therapeutics

Journal of Medicinal Chemistry

Volumn 57, Issue 19, 2014, Pages 7859-7873

  Fang, Bingliang ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN P53; CHECKPOINT KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE; RAS PROTEIN;

ARTICLE; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DNA REPAIR; DRUG STRUCTURE; GENE MUTATION; HUMAN; LETHALITY; MUTANT; ONCOGENE; ONCOGENE RAS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; MUTATION; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA DAMAGE; DRUG DISCOVERY; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASES; RAS PROTEINS;

EID: 84907942181     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500415t     Document Type: Article

References (170)

1. Vogelstein, B.; Papadopoulos, N.; Velculescu, V. E.; Zhou, S.; Diaz, L. A., Jr.; Kinzler, K. W. Cancer genome landscapes Science 2013, 339, 1546-1558
2. Patel, M. N.; Halling-Brown, M. D.; Tym, J. E.; Workman, P.; Al-Lazikani, B. Objective assessment of cancer genes for drug discovery Nat. Rev. Drug Discovery 2013, 12, 35-50
3. Hartwell, L. H.; Szankasi, P.; Roberts, C. J.; Murray, A. W.; Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs Science 1997, 278, 1064-1068
4. Dobzhansky, T. H. Genetics of natural populations. XIII. Recombination and variability and populations of drosophila pseudoobscura Genetics 1946, 31, 269-290
5. Lucchesi, J. C. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster Genetics 1968, 59, 37-44
6. Farmer, H.; McCabe, N.; Lord, C. J.; Tutt, A. N.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I.; Knights, C.; Martin, N. M.; Jackson, S. P.; Smith, G. C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 2005, 434, 917-921
7. Dolma, S.; Lessnick, S. L.; Hahn, W. C.; Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells Cancer Cell 2003, 3, 285-296
8. Guo, W.; Wu, S.; Liu, J.; Fang, B. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota Cancer Res. 2008, 68, 7403-7408
9. Barbie, D. A.; Tamayo, P.; Boehm, J. S.; Kim, S. Y.; Moody, S. E.; Dunn, I. F.; Schinzel, A. C.; Sandy, P.; Meylan, E.; Scholl, C.; Frohling, S.; Chan, E. M.; Sos, M. L.; Michel, K.; Mermel, C.; Silver, S. J.; Weir, B. A.; Reiling, J. H.; Sheng, Q.; Gupta, P. B.; Wadlow, R. C.; Le, H.; Hoersch, S.; Wittner, B. S.; Ramaswamy, S.; Livingston, D. M.; Sabatini, D. M.; Meyerson, M.; Thomas, R. K.; Lander, E. S.; Mesirov, J. P.; Root, D. E.; Gilliland, D. G.; Jacks, T.; Hahn, W. C. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Nature 2009, 462, 108-112
10. Luo, J.; Emanuele, M. J.; Li, D.; Creighton, C. J.; Schlabach, M. R.; Westbrook, T. F.; Wong, K. K.; Elledge, S. J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 2009, 137, 835-848
11. Puyol, M.; Martin, A.; Dubus, P.; Mulero, F.; Pizcueta, P.; Khan, G.; Guerra, C.; Santamaria, D.; Barbacid, M. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma Cancer Cell 2010, 18, 63-73
12. Astsaturov, I.; Ratushny, V.; Sukhanova, A.; Einarson, M. B.; Bagnyukova, T.; Zhou, Y.; Devarajan, K.; Silverman, J. S.; Tikhmyanova, N.; Skobeleva, N.; Pecherskaya, A.; Nasto, R. E.; Sharma, C.; Jablonski, S. A.; Serebriiskii, I. G.; Weiner, L. M.; Golemis, E. A. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies Sci. Signaling 2010, 3, ra67
13. Whitehurst, A. W.; Bodemann, B. O.; Cardenas, J.; Ferguson, D.; Girard, L.; Peyton, M.; Minna, J. D.; Michnoff, C.; Hao, W.; Roth, M. G.; Xie, X. J.; White, M. A. Synthetic lethal screen identification of chemosensitizer loci in cancer cells Nature 2007, 446, 815-819
14. Dai, B.; Yoo, S. Y.; Bartholomeusz, G.; Graham, R. A.; Majidi, M.; Yan, S.; Meng, J.; Ji, L.; Coombes, K.; Minna, J. D.; Fang, B.; Roth, J. A. KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer Cancer Res. 2013, 73, 5532-5543
15. Kaelin, W. G., Jr. The concept of synthetic lethality in the context of anticancer therapy Nat. Rev. Cancer 2005, 5, 689-698
16. Le Meur, N.; Gentleman, R. Modeling synthetic lethality Genome Biol. 2008, 9, R135
17. Tong, A. H.; Lesage, G.; Bader, G. D.; Ding, H.; Xu, H.; Xin, X.; Young, J.; Berriz, G. F.; Brost, R. L.; Chang, M.; Chen, Y.; Cheng, X.; Chua, G.; Friesen, H.; Goldberg, D. S.; Haynes, J.; Humphries, C.; He, G.; Hussein, S.; Ke, L.; Krogan, N.; Li, Z.; Levinson, J. N.; Lu, H.; Menard, P.; Munyana, C.; Parsons, A. B.; Ryan, O.; Tonikian, R.; Roberts, T.; Sdicu, A. M.; Shapiro, J.; Sheikh, B.; Suter, B.; Wong, S. L.; Zhang, L. V.; Zhu, H.; Burd, C. G.; Munro, S.; Sander, C.; Rine, J.; Greenblatt, J.; Peter, M.; Bretscher, A.; Bell, G.; Roth, F. P.; Brown, G. W.; Andrews, B.; Bussey, H.; Boone, C. Global mapping of the yeast genetic interaction network Science 2004, 303, 808-813
18. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 mutations in human cancers Science 1991, 253, 49-53
19. Olivier, M.; Hollstein, M.; Hainaut, P. TP53 mutations in human cancers: origins, consequences, and clinical use Cold Spring Harbor Perspect. Biol. 2010, 2, a001008
20. Bartkova, J.; Horejsi, Z.; Koed, K.; Kraemer, A.; Tort, F.; Zieger, K.; Guldberg, P.; Sehested, M.; Nesland, J. M.; Lukas, C.; Orntoft, T.; Lukas, J.; Bartek, J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis Nature 2005, 434, 864-870
21. Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer Nature 2001, 411, 366-374
22. Langelier, M. F.; Planck, J. L.; Roy, S.; Pascal, J. M. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1 Science 2012, 336, 728-732
23. Ali, A. A.; Timinszky, G.; Arribas-Bosacoma, R.; Kozlowski, M.; Hassa, P. O.; Hassler, M.; Ladurner, A. G.; Pearl, L. H.; Oliver, A. W. The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks Nat. Struct. Mol. Biol. 2012, 19, 685-692
24. Luijsterburg, M. S.; Lindh, M.; Acs, K.; Vrouwe, M. G.; Pines, A.; van, A. H.; Mullenders, L. H.; Dantuma, N. P. DDB2 promotes chromatin decondensation at UV-induced DNA damage J. Cell Biol. 2012, 197, 267-281
25. Goodarzi, A. A.; Jeggo, P. A. The repair and signaling responses to DNA double-strand breaks Adv. Genet. 2013, 82, 1-45
26. Sperka, T.; Wang, J.; Rudolph, K. L. DNA damage checkpoints in stem cells, ageing and cancer Nat. Rev. Mol. Cell Biol. 2012, 13, 579-590
27. Matsuoka, S.; Ballif, B. A.; Smogorzewska, A.; McDonald, E. R., III; Hurov, K. E.; Luo, J.; Bakalarski, C. E.; Zhao, Z.; Solimini, N.; Lerenthal, Y.; Shiloh, Y.; Gygi, S. P.; Elledge, S. J. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage Science 2007, 316, 1160-1166
28. Chen, J.; Silver, D. P.; Walpita, D.; Cantor, S. B.; Gazdar, A. F.; Tomlinson, G.; Couch, F. J.; Weber, B. L.; Ashley, T.; Livingston, D. M.; Scully, R. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells Mol. Cell 1998, 2, 317-328
29. Pellegrini, L.; Yu, D. S.; Lo, T.; Anand, S.; Lee, M.; Blundell, T. L.; Venkitaraman, A. R. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex Nature 2002, 420, 287-293
30. Ramsden, D. A.; Gellert, M. Ku protein stimulates DNA end joining by mammalian DNA ligases: a direct role for Ku in repair of DNA double-strand breaks EMBO J. 1998, 17, 609-614
31. Simsek, D.; Jasin, M. Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4-ligase IV during chromosomal translocation formation Nat. Struct. Mol. Biol. 2010, 17, 410-416
32. Gibson, B. A.; Kraus, W. L. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs Nat. Rev. Mol. Cell Biol. 2012, 13, 411-424
33. Kim, M. Y.; Zhang, T.; Kraus, W. L. Poly(ADP-ribosyl)ation by PARP-1: "PAR-laying" NAD+ into a nuclear signal Genes Dev. 2005, 19, 1951-1967
34. Ruscetti, T.; Lehnert, B. E.; Halbrook, J.; Trong, H. L.; Hoekstra, M. F.; Chen, D. J.; Peterson, S. R. Stimulation of the DNA-dependent protein kinase by poly(ADP-ribose) polymerase J. Biol. Chem. 1998, 273, 14461-14467
35. Ahel, I.; Ahel, D.; Matsusaka, T.; Clark, A. J.; Pines, J.; Boulton, S. J.; West, S. C. Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins Nature 2008, 451, 81-85
36. Haince, J. F.; Kozlov, S.; Dawson, V. L.; Dawson, T. M.; Hendzel, M. J.; Lavin, M. F.; Poirier, G. G. Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents J. Biol. Chem. 2007, 282, 16441-16453
37. Chou, D. M.; Adamson, B.; Dephoure, N. E.; Tan, X.; Nottke, A. C.; Hurov, K. E.; Gygi, S. P.; Colaiacovo, M. P.; Elledge, S. J. A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 18475-18480
38. Pleschke, J. M.; Kleczkowska, H. E.; Strohm, M.; Althaus, F. R. Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins J. Biol. Chem. 2000, 275, 40974-40980
39. Wei, L.; Nakajima, S.; Hsieh, C. L.; Kanno, S.; Masutani, M.; Levine, A. S.; Yasui, A.; Lan, L. Damage response of XRCC1 at sites of DNA single strand breaks is regulated by phosphorylation and ubiquitylation after degradation of poly(ADP-ribose) J. Cell Sci. 2013, 126, 4414-4423
40. Prasad, R.; Lavrik, O. I.; Kim, S. J.; Kedar, P.; Yang, X. P.; Vande Berg, B. J.; Wilson, S. H. DNA polymerase beta-mediated long patch base excision repair. Poly(ADP-ribose)polymerase-1 stimulates strand displacement DNA synthesis J. Biol. Chem. 2001, 276, 32411-32414
41. Sukhanova, M. V.; Khodyreva, S. N.; Lebedeva, N. A.; Prasad, R.; Wilson, S. H.; Lavrik, O. I. Human base excision repair enzymes apurinic/apyrimidinic endonuclease1 (APE1), DNA polymerase beta and poly(ADP-ribose) polymerase 1: interplay between strand-displacement DNA synthesis and proofreading exonuclease activity Nucleic Acids Res. 2005, 33, 1222-1229
42. Ahel, D.; Horejsi, Z.; Wiechens, N.; Polo, S. E.; Garcia-Wilson, E.; Ahel, I.; Flynn, H.; Skehel, M.; West, S. C.; Jackson, S. P.; Owen-Hughes, T.; Boulton, S. J. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1 Science 2009, 325, 1240-1243
43. Couto, C. A.; Wang, H. Y.; Green, J. C.; Kiely, R.; Siddaway, R.; Borer, C.; Pears, C. J.; Lakin, N. D. PARP regulates nonhomologous end joining through retention of Ku at double-strand breaks J. Cell Biol. 2011, 194, 367-375
44. Mansour, W. Y.; Borgmann, K.; Petersen, C.; Dikomey, E.; Dahm-Daphi, J. The absence of Ku but not defects in classical non-homologous end-joining is required to trigger PARP1-dependent end-joining DNA Repair 2013, 12, 1134-1142
45. Aguilar-Quesada, R.; Munoz-Gamez, J. A.; Martin-Oliva, D.; Peralta, A.; Valenzuela, M. T.; Matinez-Romero, R.; Quiles-Perez, R.; Menissier-de Murcia, J.; de Murcia, G.; Ruiz de Almodovar, M.; Oliver, F. J. Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition BMC Mol. Biol. 2007, 8, 29
46. Yang, Y. G.; Cortes, U.; Patnaik, S.; Jasin, M.; Wang, Z. Q. Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks Oncogene 2004, 23, 3872-3882
47. Shibata, A.; Kamada, N.; Masumura, K.; Nohmi, T.; Kobayashi, S.; Teraoka, H.; Nakagama, H.; Sugimura, T.; Suzuki, H.; Masutani, M. PARP-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent Oncogene 2005, 24, 1328-1337
48. Menissier de Murcia, J.; Ricoul, M.; Tartier, L.; Niedergang, C.; Huber, A.; Dantzer, F.; Schreiber, V.; Ame, J. C.; Dierich, A.; LeMeur, M.; Sabatier, L.; Chambon, P.; de Murcia, G. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse EMBO J. 2003, 22, 2255-2263
49. de Murcia, J. M.; Niedergang, C.; Trucco, C.; Ricoul, M.; Dutrillaux, B.; Mark, M.; Oliver, F. J.; Masson, M.; Dierich, A.; LeMeur, M.; Walztinger, C.; Chambon, P.; de Murcia, G. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 7303-7307
50. Bryant, H. E.; Schultz, N.; Thomas, H. D.; Parker, K. M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N. J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 2005, 434, 913-917 (Erratum appears in
51. Nature 2007, 447, 346
52. Patel, A. G.; Sarkaria, J. N.; Kaufmann, S. H. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 3406-3411
53. Bryant, H. E.; Helleday, T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair Nucleic Acids Res. 2006, 34, 1685-1691
54. Hegan, D. C.; Lu, Y.; Stachelek, G. C.; Crosby, M. E.; Bindra, R. S.; Glazer, P. M. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130 Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 2201-2206
55. Antoniou, A.; Pharoah, P. D.; Narod, S.; Risch, H. A.; Eyfjord, J. E.; Hopper, J. L.; Loman, N.; Olsson, H.; Johannsson, O.; Borg, A.; Pasini, B.; Radice, P.; Manoukian, S.; Eccles, D. M.; Tang, N.; Olah, E.; Anton-Culver, H.; Warner, E.; Lubinski, J.; Gronwald, J.; Gorski, B.; Tulinius, H.; Thorlacius, S.; Eerola, H.; Nevanlinna, H.; Syrjakoski, K.; Kallioniemi, O. P.; Thompson, D.; Evans, C.; Peto, J.; Lalloo, F.; Evans, D. G.; Easton, D. F. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies Am. J. Hum. Genet. 2003, 72, 1117-1130
56. Erratum appears in Am. J. Hum. Genet. 2003, 73, 709
57. Thompson, D.; Easton, D. F.; Breast Cancer Linkage Consortium Cancer incidence in BRCA1 mutation carriers J. Natl. Cancer Inst. 2002, 94, 1358-1365
58. Roy, R.; Chun, J.; Powell, S. N. BRCA1 and BRCA2: different roles in a common pathway of genome protection Nat. Rev. Cancer 2012, 12, 68-78
59. Thiemermann, C.; Bowes, J.; Myint, F. P.; Vane, J. R. Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 679-683
60. Eliasson, M. J.; Sampei, K.; Mandir, A. S.; Hurn, P. D.; Traystman, R. J.; Bao, J.; Pieper, A.; Wang, Z. Q.; Dawson, T. M.; Snyder, S. H.; Dawson, V. L. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia Nat. Med. 1997, 3, 1089-1095
61. Ha, H. C.; Hester, L. D.; Snyder, S. H. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 3270-3275
62. Calabrese, C. R.; Almassy, R.; Barton, S.; Batey, M. A.; Calvert, A. H.; Canan-Koch, S.; Durkacz, B. W.; Hostomsky, Z.; Kumpf, R. A.; Kyle, S.; Li, J.; Maegley, K.; Newell, D. R.; Notarianni, E.; Stratford, I. J.; Skalitzky, D.; Thomas, H. D.; Wang, L. Z.; Webber, S. E.; Williams, K. J.; Curtin, N. J. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361 J. Natl. Cancer Inst. 2004, 96, 56-67
63. Jagtap, P.; Szabo, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors Nat. Rev. Drug Discovery 2005, 4, 421-440
64. Rouleau, M.; Patel, A.; Hendzel, M. J.; Kaufmann, S. H.; Poirier, G. G. PARP inhibition: PARP1 and beyond Nat. Rev. Cancer 2010, 10, 293-301
65. Ferraris, D. V. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic J. Med. Chem. 2010, 53, 4561-4584
66. Wahlberg, E.; Karlberg, T.; Kouznetsova, E.; Markova, N.; Macchiarulo, A.; Thorsell, A. G.; Pol, E.; Frostell, A.; Ekblad, T.; Oncu, D.; Kull, B.; Robertson, G. M.; Pellicciari, R.; Schuler, H.; Weigelt, J. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors Nat. Biotechnol. 2012, 30, 283-288
67. Skalitzky, D. J.; Marakovits, J. T.; Maegley, K. A.; Ekker, A.; Yu, X. H.; Hostomsky, Z.; Webber, S. E.; Eastman, B. W.; Almassy, R.; Li, J.; Curtin, N. J.; Newell, D. R.; Calvert, A. H.; Griffin, R. J.; Golding, B. T. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors J. Med. Chem. 2003, 46, 210-213
68. Weston, V. J.; Oldreive, C. E.; Skowronska, A.; Oscier, D. G.; Pratt, G.; Dyer, M. J.; Smith, G.; Powell, J. E.; Rudzki, Z.; Kearns, P.; Moss, P. A.; Taylor, A. M.; Stankovic, T. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo Blood 2010, 116, 4578-4587
69. Vilar, E.; Bartnik, C. M.; Stenzel, S. L.; Raskin, L.; Ahn, J.; Moreno, V.; Mukherjee, B.; Iniesta, M. D.; Morgan, M. A.; Rennert, G.; Gruber, S. B. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers Cancer Res. 2011, 71, 2632-2642
70. Postel-Vinay, S.; Bajrami, I.; Friboulet, L.; Elliott, R.; Fontebasso, Y.; Dorvault, N.; Olaussen, K. A.; Andre, F.; Soria, J. C.; Lord, C. J.; Ashworth, A. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer Oncogene 2013, 32, 5377-5387
71. Williamson, C. T.; Kubota, E.; Hamill, J. D.; Klimowicz, A.; Ye, R.; Muzik, H.; Dean, M.; Tu, L.; Gilley, D.; Magliocco, A. M.; McKay, B. C.; Bebb, D. G.; Lees-Miller, S. P. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53 EMBO Mol. Med. 2012, 4, 515-527
72. Mendes-Pereira, A. M.; Martin, S. A.; Brough, R.; McCarthy, A.; Taylor, J. R.; Kim, J. S.; Waldman, T.; Lord, C. J.; Ashworth, A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors EMBO Mol. Med. 2009, 1, 315-322
73. Lord, C. J.; McDonald, S.; Swift, S.; Turner, N. C.; Ashworth, A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity DNA Repair 2008, 7, 2010-2019
74. Cardnell, R. J.; Feng, Y.; Diao, L.; Fan, Y. H.; Masrorpour, F.; Wang, J.; Shen, Y.; Mills, G. B.; Minna, J. D.; Heymach, J. V.; Byers, L. A. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer Clin. Cancer Res. 2013, 19, 6322-6328
75. Brenner, J. C.; Ateeq, B.; Li, Y.; Yocum, A. K.; Cao, Q.; Asangani, I. A.; Patel, S.; Wang, X.; Liang, H.; Yu, J.; Palanisamy, N.; Siddiqui, J.; Yan, W.; Cao, X.; Mehra, R.; Sabolch, A.; Basrur, V.; Lonigro, R. J.; Yang, J.; Tomlins, S. A.; Maher, C. A.; Elenitoba-Johnson, K. S.; Hussain, M.; Navone, N. M.; Pienta, K. J.; Varambally, S.; Feng, F. Y.; Chinnaiyan, A. M. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer Cancer Cell 2011, 19, 664-678
76. Nowsheen, S.; Cooper, T.; Stanley, J. A.; Yang, E. S. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells PLoS One 2012, 7, e46614
77. Plummer, R.; Jones, C.; Middleton, M.; Wilson, R.; Evans, J.; Olsen, A.; Curtin, N.; Boddy, A.; McHugh, P.; Newell, D.; Harris, A.; Johnson, P.; Steinfeldt, H.; Dewji, R.; Wang, D.; Robson, L.; Calvert, H. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors Clin. Cancer Res. 2008, 14, 7917-7923
78. Plummer, R.; Lorigan, P.; Steven, N.; Scott, L.; Middleton, M. R.; Wilson, R. H.; Mulligan, E.; Curtin, N.; Wang, D.; Dewji, R.; Abbattista, A.; Gallo, J.; Calvert, H. A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation Cancer Chemother. Pharmacol. 2013, 71, 1191-1199
79. Fong, P. C.; Yap, T. A.; Boss, D. S.; Carden, C. P.; Mergui-Roelvink, M.; Gourley, C.; De Greve, J.; Lubinski, J.; Shanley, S.; Messiou, C.; A'Hern, R.; Tutt, A.; Ashworth, A.; Stone, J.; Carmichael, J.; Schellens, J. H.; de Bono, J. S.; Kaye, S. B. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J. Clin. Oncol. 2010, 28, 2512-2519
80. Tutt, A.; Robson, M.; Garber, J. E.; Domchek, S. M.; Audeh, M. W.; Weitzel, J. N.; Friedlander, M.; Arun, B.; Loman, N.; Schmutzler, R. K.; Wardley, A.; Mitchell, G.; Earl, H.; Wickens, M.; Carmichael, J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 2010, 376, 235-244
81. Bundred, N.; Gardovskis, J.; Jaskiewicz, J.; Eglitis, J.; Paramonov, V.; McCormack, P.; Swaisland, H.; Cavallin, M.; Parry, T.; Carmichael, J.; Dixon, J. M. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery Invest. New Drugs 2013, 31, 949-958
82. Yamamoto, N.; Nokihara, H.; Yamada, Y.; Goto, Y.; Tanioka, M.; Shibata, T.; Yamada, K.; Asahina, H.; Kawata, T.; Shi, X.; Tamura, T. A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors Cancer Sci. 2012, 103, 504-509
83. Rajan, A.; Carter, C. A.; Kelly, R. J.; Gutierrez, M.; Kummar, S.; Szabo, E.; Yancey, M. A.; Ji, J.; Mannargudi, B.; Woo, S.; Spencer, S.; Figg, W. D.; Giaccone, G. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors Clin. Cancer Res. 2012, 18, 2344-2351
84. Liu, J. F.; Tolaney, S. M.; Birrer, M.; Fleming, G. F.; Buss, M. K.; Dahlberg, S. E.; Lee, H.; Whalen, C.; Tyburski, K.; Winer, E.; Ivy, P.; Matulonis, U. A. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer Eur. J. Cancer 2013, 49, 2972-2978
85. Kaye, S. B.; Lubinski, J.; Matulonis, U.; Ang, J. E.; Gourley, C.; Karlan, B. Y.; Amnon, A.; Bell-McGuinn, K. M.; Chen, L. M.; Friedlander, M.; Safra, T.; Vergote, I.; Wickens, M.; Lowe, E. S.; Carmichael, J.; Kaufman, B. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer J. Clin.Oncol. 2012, 30, 372-379
86. Kummar, S.; Chen, A.; Ji, J.; Zhang, Y.; Reid, J. M.; Ames, M.; Jia, L.; Weil, M.; Speranza, G.; Murgo, A. J.; Kinders, R.; Wang, L.; Parchment, R. E.; Carter, J.; Stotler, H.; Rubinstein, L.; Hollingshead, M.; Melillo, G.; Pommier, Y.; Bonner, W.; Tomaszewski, J. E.; Doroshow, J. H. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas Cancer Res. 2011, 71, 5626-5634
87. Sandhu, S. K.; Schelman, W. R.; Wilding, G.; Moreno, V.; Baird, R. D.; Miranda, S.; Hylands, L.; Riisnaes, R.; Forster, M.; Omlin, A.; Kreischer, N.; Thway, K.; Gevensleben, H.; Sun, L.; Loughney, J.; Chatterjee, M.; Toniatti, C.; Carpenter, C. L.; Iannone, R.; Kaye, S. B.; de Bono, J. S.; Wenham, R. M. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial Lancet Oncol. 2013, 14, 882-892
88. de Bono, J. S.; Mina, L. A.; Gonzalez, M.; Curtin, N. J.; Wang, E.; Henshaw, J. W.; Chadha, M.; Sachdev, J. C.; Matei, D.; Jameson, G. S.; Ong, M.; Basu, B.; Wainberg, Z. A.; Byers, L. A.; Chugh, R.; Dorr, A.; Kaye, S. B.; Ramanathan, R. K. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumor J. Clin. Oncol. 2013, 31, 2580
89. Banin, S.; Moyal, L.; Shieh, S.; Taya, Y.; Anderson, C. W.; Chessa, L.; Smorodinsky, N. I.; Prives, C.; Reiss, Y.; Shiloh, Y.; Ziv, Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage Science 1998, 281, 1674-1677
90. Chehab, N. H.; Malikzay, A.; Appel, M.; Halazonetis, T. D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53 Genes Dev. 2000, 14, 278-288
91. Tibbetts, R. S.; Brumbaugh, K. M.; Williams, J. M.; Sarkaria, J. N.; Cliby, W. A.; Shieh, S. Y.; Taya, Y.; Prives, C.; Abraham, R. T. A role for ATR in the DNA damage-induced phosphorylation of p53 Genes Dev. 1999, 13, 152-157
92. Donzelli, M.; Draetta, G. F. Regulating mammalian checkpoints through Cdc25 inactivation EMBO Rep. 2003, 4, 671-677
93. Cliby, W. A.; Roberts, C. J.; Cimprich, K. A.; Stringer, C. M.; Lamb, J. R.; Schreiber, S. L.; Friend, S. H. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints EMBO J. 1998, 17, 159-169
94. Uto, K.; Inoue, D.; Shimuta, K.; Nakajo, N.; Sagata, N. Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism EMBO J. 2004, 23, 3386-3396
95. Innocente, S. A.; Abrahamson, J. L.; Cogswell, J. P.; Lee, J. M. p53 regulates a G2 checkpoint through cyclin B1 Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 2147-2152
96. Reinhardt, H. C.; Aslanian, A. S.; Lees, J. A.; Yaffe, M. B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage Cancer Cell 2007, 11, 175-189
97. Jiang, H.; Reinhardt, H. C.; Bartkova, J.; Tommiska, J.; Blomqvist, C.; Nevanlinna, H.; Bartek, J.; Yaffe, M. B.; Hemann, M. T. The combined status of ATM and p53 link tumor development with therapeutic response Genes Dev. 2009, 23, 1895-1909
98. Sullivan, K. D.; Padilla-Just, N.; Henry, R. E.; Porter, C. C.; Kim, J.; Tentler, J. J.; Eckhardt, S. G.; Tan, A. C.; DeGregori, J.; Espinosa, J. M. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53 Nat. Chem. Biol. 2012, 8, 646-654
99. Batey, M. A.; Zhao, Y.; Kyle, S.; Richardson, C.; Slade, A.; Martin, N. M.; Lau, A.; Newell, D. R.; Curtin, N. J. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer Mol. Cancer Ther. 2013, 12, 959-967
100. Nghiem, P.; Park, P. K.; Kim, Y.; Vaziri, C.; Schreiber, S. L. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 9092-9097
101. Sangster-Guity, N.; Conrad, B. H.; Papadopoulos, N.; Bunz, F. ATR mediates cisplatin resistance in a p53 genotype-specific manner Oncogene 2011, 30, 2526-2533
102. Murga, M.; Campaner, S.; Lopez-Contreras, A. J.; Toledo, L. I.; Soria, R.; Montana, M. F.; D'Artista, L.; Schleker, T.; Guerra, C.; Garcia, E.; Barbacid, M.; Hidalgo, M.; Amati, B.; Fernandez-Capetillo, O. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors Nat. Struct. Mol. Biol. 2011, 18, 1331-1335
103. Kawasumi, M.; Lemos, B.; Bradner, J. E.; Thibodeau, R.; Kim, Y. S.; Schmidt, M.; Higgins, E.; Koo, S. W.; Angle-Zahn, A.; Chen, A.; Levine, D.; Nguyen, L.; Heffernan, T. P.; Longo, I.; Mandinova, A.; Lu, Y. P.; Conney, A. H.; Nghiem, P. Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 13716-13721
104. Sultana, R.; Abdel-Fatah, T.; Perry, C.; Moseley, P.; Albarakti, N.; Mohan, V.; Seedhouse, C.; Chan, S.; Madhusudan, S. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells PLoS One 2013, 8, e57098
105. Huntoon, C. J.; Flatten, K. S.; Wahner Hendrickson, A. E.; Huehls, A. M.; Sutor, S. L.; Kaufmann, S. H.; Karnitz, L. M. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status Cancer Res. 2013, 73, 3683-3691
106. Sultana, R.; bdel-Fatah, T.; Abbotts, R.; Hawkes, C.; Albarakati, N.; Seedhouse, C.; Ball, G.; Chan, S.; Rakha, E. A.; Ellis, I. O.; Madhusudan, S. Targeting XRCC1 deficiency in breast cancer for personalized therapy Cancer Res. 2013, 73, 1621-1634
107. Toledo, L. I.; Murga, M.; Zur, R.; Soria, R.; Rodriguez, A.; Martinez, S.; Oyarzabal, J.; Pastor, J.; Bischoff, J. R.; Fernandez-Capetillo, O. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations Nat. Struct. Mol. Biol. 2011, 18, 721-727
108. Foote, K. M.; Blades, K.; Cronin, A.; Fillery, S.; Guichard, S. S.; Hassall, L.; Hickson, I.; Jacq, X.; Jewsbury, P. J.; McGuire, T. M.; Nissink, J. W.; Odedra, R.; Page, K.; Perkins, P.; Suleman, A.; Tam, K.; Thommes, P.; Broadhurst, R.; Wood, C. Discovery of 4-{4-[(3 R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1 H -indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity J. Med. Chem. 2013, 56, 2125-2138
109. Charrier, J. D.; Durrant, S. J.; Golec, J. M.; Kay, D. P.; Knegtel, R. M.; MacCormick, S.; Mortimore, M.; O'Donnell, M. E.; Pinder, J. L.; Reaper, P. M.; Rutherford, A. P.; Wang, P. S.; Young, S. C.; Pollard, J. R. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents J. Med. Chem. 2011, 54, 2320-2330
110. Reaper, P. M.; Griffiths, M. R.; Long, J. M.; Charrier, J. D.; MacCormick, S.; Charlton, P. A.; Golec, J. M.; Pollard, J. R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR Nat. Chem. Biol. 2011, 7, 428-430
111. Fokas, E.; Prevo, R.; Pollard, J. R.; Reaper, P. M.; Charlton, P. A.; Cornelissen, B.; Vallis, K. A.; Hammond, E. M.; Olcina, M. M.; Gillies, M. W.; Muschel, R. J.; Brunner, T. B. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation Cell Death Dis. 2012, 3, e441
112. Stracker, T. H.; Usui, T.; Petrini, J. H. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response DNA Repair 2009, 8, 1047-1054
113. Ferrao, P. T.; Bukczynska, E. P.; Johnstone, R. W.; McArthur, G. A. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells Oncogene 2012, 31, 1661-1672
114. Landau, H. J.; McNeely, S. C.; Nair, J. S.; Comenzo, R. L.; Asai, T.; Friedman, H.; Jhanwar, S. C.; Nimer, S. D.; Schwartz, G. K. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells Mol. Cancer Ther. 2012, 11, 1781-1788
115. Origanti, S.; Cai, S. R.; Munir, A. Z.; White, L. S.; Piwnica-Worms, H. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells Oncogene 2013, 32, 577-588
116. Morgan, M. A.; Parsels, L. A.; Zhao, L.; Parsels, J. D.; Davis, M. A.; Hassan, M. C.; Arumugarajah, S.; Hylander-Gans, L.; Morosini, D.; Simeone, D. M.; Canman, C. E.; Normolle, D. P.; Zabludoff, S. D.; Maybaum, J.; Lawrence, T. S. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair Cancer Res. 2010, 70, 4972-4981
117. Hirao, A.; Kong, Y. Y.; Matsuoka, S.; Wakeham, A.; Ruland, J.; Yoshida, H.; Liu, D.; Elledge, S. J.; Mak, T. W. DNA damage-induced activation of p53 by the checkpoint kinase Chk2 Science 2000, 287, 1824-1827
118. Liu, Q.; Guntuku, S.; Cui, X. S.; Matsuoka, S.; Cortez, D.; Tamai, K.; Luo, G.; Carattini-Rivera, S.; DeMayo, F.; Bradley, A.; Donehower, L. A.; Elledge, S. J. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint Genes Dev. 2000, 14, 1448-1459
119. Xu, Y.; Ashley, T.; Brainerd, E. E.; Bronson, R. T.; Meyn, M. S.; Baltimore, D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma Genes Dev. 1996, 10, 2411-2422
120. Takai, H.; Naka, K.; Okada, Y.; Watanabe, M.; Harada, N.; Saito, S.; Anderson, C. W.; Appella, E.; Nakanishi, M.; Suzuki, H.; Nagashima, K.; Sawa, H.; Ikeda, K.; Motoyama, N. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription EMBO J. 2002, 21, 5195-5205
121. Brown, E. J.; Baltimore, D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality Genes Dev. 2000, 14, 397-402
122. Azorsa, D. O.; Gonzales, I. M.; Basu, G. D.; Choudhary, A.; Arora, S.; Bisanz, K. M.; Kiefer, J. A.; Henderson, M. C.; Trent, J. M.; Von Hoff, D. D.; Mousses, S. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer J. Transl. Med. 2009, 7, 43
123. Seto, T.; Esaki, T.; Hirai, F.; Arita, S.; Nosaki, K.; Makiyama, A.; Kometani, T.; Fujimoto, C.; Hamatake, M.; Takeoka, H.; Agbo, F.; Shi, X. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours Cancer Chemother. Pharmacol. 2013, 72, 619-627
124. Wang, Q.; Fan, S.; Eastman, A.; Worland, P. J.; Sausville, E. A.; O'Connor, P. M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53 J. Natl. Cancer Inst. 1996, 88, 956-965
125. Gojo, I.; Perl, A.; Luger, S.; Baer, M. R.; Norsworthy, K. J.; Bauer, K. S.; Tidwell, M.; Fleckinger, S.; Carroll, M.; Sausville, E. A. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome Invest. New Drugs 2013, 31, 1217-1227
126. Li, T.; Christensen, S. D.; Frankel, P. H.; Margolin, K. A.; Agarwala, S. S.; Luu, T.; Mack, P. C.; Lara, P. N., Jr.; Gandara, D. R. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial Invest. New Drugs 2012, 30, 741-748
127. Guzi, T. J.; Paruch, K.; Dwyer, M. P.; Labroli, M.; Shanahan, F.; Davis, N.; Taricani, L.; Wiswell, D.; Seghezzi, W.; Penaflor, E.; Bhagwat, B.; Wang, W.; Gu, D.; Hsieh, Y.; Lee, S.; Liu, M.; Parry, D. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening Mol. Cancer Ther. 2011, 10, 591-602
128. Arora, S.; Bisanz, K. M.; Peralta, L. A.; Basu, G. D.; Choudhary, A.; Tibes, R.; Azorsa, D. O. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells Gynecol. Oncol. 2010, 118, 220-227
129. Karp, J. E.; Thomas, B. M.; Greer, J. M.; Sorge, C.; Gore, S. D.; Pratz, K. W.; Smith, B. D.; Flatten, K. S.; Peterson, K.; Schneider, P.; Mackey, K.; Freshwater, T.; Levis, M. J.; McDevitt, M. A.; Carraway, H. E.; Gladstone, D. E.; Showel, M. M.; Loechner, S.; Parry, D. A.; Horowitz, J. A.; Isaacs, R.; Kaufmann, S. H. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias Clin. Cancer Res. 2012, 18, 6723-6731
130. Weiss, G. J.; Donehower, R. C.; Iyengar, T.; Ramanathan, R. K.; Lewandowski, K.; Westin, E.; Hurt, K.; Hynes, S. M.; Anthony, S. P.; McKane, S. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500mg/m(2) every 21 days in patients with cancer Invest. New Drugs 2013, 31, 136-144
131. Maugeri-Sacca, M.; Bartucci, M.; De Maria, R. Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy Cancer Treat. Rev. 2013, 39, 525-533
132. Jobson, A. G.; Lountos, G. T.; Lorenzi, P. L.; Llamas, J.; Connelly, J.; Cerna, D.; Tropea, J. E.; Onda, A.; Zoppoli, G.; Kondapaka, S.; Zhang, G.; Caplen, N. J.; Cardellina, J. H.; Yoo, S. S.; Monks, A.; Self, C.; Waugh, D. S.; Shoemaker, R. H.; Pommier, Y. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1 H -indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide] J. Pharmacol. Exp. Ther. 2009, 331, 816-826
133. Caldwell, J. J.; Welsh, E. J.; Matijssen, C.; Anderson, V. E.; Antoni, L.; Boxall, K.; Urban, F.; Hayes, A.; Raynaud, F. I.; Rigoreau, L. J.; Raynham, T.; Aherne, G. W.; Pearl, L. H.; Oliver, A. W.; Garrett, M. D.; Collins, I. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2 J. Med. Chem. 2011, 54, 580-590
134. Fernandez-Medarde, A.; Santos, E. Ras in cancer and developmental diseases Genes Cancer 2011, 2, 344-358
135. Pells, S.; Divjak, M.; Romanowski, P.; Impey, H.; Hawkins, N. J.; Clarke, A. R.; Hooper, M. L.; Williamson, D. J. Developmentally-regulated expression of murine K-ras isoforms Oncogene 1997, 15, 1781-1786
136. Bar-Sagi, D.; Hall, A. Ras and Rho GTPases: a family reunion Cell 2000, 103, 227-238
137. Hoa, M.; Davis, S. L.; Ames, S. J.; Spanjaard, R. A. Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma Cancer Res. 2002, 62, 7154-7156
138. Coleman, W. B.; Throneburg, D. B.; Grisham, J. W.; Smith, G. J. Overexpression of c-K-ras, c-N-ras and transforming growth factor beta co-segregate with tumorigenicity in morphologically transformed C3H 10T1/2 cell lines Carcinogenesis 1994, 15, 1005-1012
139. Buday, L.; Downward, J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor Cell 1993, 73, 611-620
140. Johnson, S. M.; Grosshans, H.; Shingara, J.; Byrom, M.; Jarvis, R.; Cheng, A.; Labourier, E.; Reinert, K. L.; Brown, D.; Slack, F. J. RAS is regulated by the let-7 microRNA family Cell 2005, 120, 635-647
141. Bernhard, E. J.; Stanbridge, E. J.; Gupta, S.; Gupta, A. K.; Soto, D.; Bakanauskas, V. J.; Cerniglia, G. J.; Muschel, R. J.; McKenna, W. G. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines Cancer Res. 2000, 60, 6597-6600
142. Diaz, L. A., Jr.; Williams, R. T.; Wu, J.; Kinde, I.; Hecht, J. R.; Berlin, J.; Allen, B.; Bozic, I.; Reiter, J. G.; Nowak, M. A.; Kinzler, K. W.; Oliner, K. S.; Vogelstein, B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 2012, 486, 537-540
143. Hancock, J. F. Ras proteins: different signals from different locations Nat. Rev. Mol. Cell Biol. 2003, 4, 373-384
144. Sebti, S. M.; Adjei, A. A. Farnesyltransferase inhibitors Semin. Oncol. 2004, 31, 28-39
145. Berndt, N.; Hamilton, A. D.; Sebti, S. M. Targeting protein prenylation for cancer therapy Nat. Rev. Cancer 2011, 11, 775-791
146. Winter-Vann, A. M.; Baron, R. A.; Wong, W.; dela Cruz, J.; York, J. D.; Gooden, D. M.; Bergo, M. O.; Young, S. G.; Toone, E. J.; Casey, P. J. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 4336-4341
147. Ostrem, J. M.; Peters, U.; Sos, M. L.; Wells, J. A.; Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions Nature 2013, 503, 548-551
148. Shima, F.; Yoshikawa, Y.; Ye, M.; Araki, M.; Matsumoto, S.; Liao, J.; Hu, L.; Sugimoto, T.; Ijiri, Y.; Takeda, A.; Nishiyama, Y.; Sato, C.; Muraoka, S.; Tamura, A.; Osoda, T.; Tsuda, K.; Miyakawa, T.; Fukunishi, H.; Shimada, J.; Kumasaka, T.; Yamamoto, M.; Kataoka, T. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 8182-8187
149. Rusconi, P.; Caiola, E.; Broggini, M. RAS/RAF/MEK inhibitors in oncology Curr. Med. Chem. 2012, 19, 1164-1176
150. Kim, E. S.; Herbst, R. S.; Wistuba, I. I.; Lee, J. J.; Blumenschein, G. R., Jr.; Tsao, A.; Stewart, D. J.; Hicks, M. E.; Erasmus, J., Jr.; Gupta, S.; Alden, C. M.; Liu, S.; Tang, X.; Khuri, F. R.; Tran, H. T.; Johnson, B. E.; Heymach, J. V.; Mao, L.; Fossella, F.; Kies, M. S.; Papadimitrakopoulou, V.; Davis, S. E.; Lippman, S. M.; Hong, W. K. The BATTLE trial: personalizing therapy for lung cancer Cancer Discovery 2011, 1, 44-53
151. Heidorn, S. J.; Milagre, C.; Whittaker, S.; Nourry, A.; Niculescu-Duvas, I.; Dhomen, N.; Hussain, J.; Reis-Filho, J. S.; Springer, C. J.; Pritchard, C.; Marais, R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 2010, 140, 209-221
152. Callahan, M. K.; Rampal, R.; Harding, J. J.; Klimek, V. M.; Chung, Y. R.; Merghoub, T.; Wolchok, J. D.; Solit, D. B.; Rosen, N.; Abdel-Wahab, O.; Levine, R. L.; Chapman, P. B. Progression of RAS-mutant leukemia during RAF inhibitor treatment N. Engl. J. Med. 2012, 367, 2316-2321
153. Tanaka, N.; Ishihara, M.; Kitagawa, M.; Harada, H.; Kimura, T.; Matsuyama, T.; Lamphier, M. S.; Aizawa, S.; Mak, T. W.; Taniguchi, T. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1 Cell 1994, 77, 829-839
154. Serrano, M.; Lin, A. W.; McCurrach, M. E.; Beach, D.; Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a Cell 1997, 88, 593-602
155. Cox, A. D.; Der, C. J. The dark side of Ras: regulation of apoptosis Oncogene 2003, 22, 8999-9006
156. Vicent, S.; Chen, R.; Sayles, L. C.; Lin, C.; Walker, R. G.; Gillespie, A. K.; Subramanian, A.; Hinkle, G.; Yang, X.; Saif, S.; Root, D. E.; Huff, V.; Hahn, W. C.; Sweet-Cordero, E. A. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models J. Clin. Invest. 2010, 120, 3940-3952
157. Singh, A.; Greninger, P.; Rhodes, D.; Koopman, L.; Violette, S.; Bardeesy, N.; Settleman, J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival Cancer Cell 2009, 15, 489-500
158. Degenhardt, Y.; Lampkin, T. Targeting Polo-like kinase in cancer therapy Clin. Cancer Res. 2010, 16, 384-389
159. Dickson, M. A.; Tap, W. D.; Keohan, M. L.; D'Angelo, S. P.; Gounder, M. M.; Antonescu, C. R.; Landa, J.; Qin, L. X.; Rathbone, D. D.; Condy, M. M.; Ustoyev, Y.; Crago, A. M.; Singer, S.; Schwartz, G. K. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma J. Clin. Oncol. 2013, 31, 2024-2028
160. Torrance, C. J.; Agrawal, V.; Vogelstein, B.; Kinzler, K. W. Use of isogenic human cancer cells for high-throughput screening and drug discovery Nat. Biotechnol. 2001, 19, 940-945
161. Shaw, A. T.; Winslow, M. M.; Magendantz, M.; Ouyang, C.; Dowdle, J.; Subramanian, A.; Lewis, T. A.; Maglathin, R. L.; Tolliday, N.; Jacks, T. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 8773-8778
162. Yagoda, N.; von Rechenberg, M.; Zaganjor, E.; Bauer, A. J.; Yang, W. S.; Fridman, D. J.; Wolpaw, A. J.; Smukste, I.; Peltier, J. M.; Boniface, J. J.; Smith, R.; Lessnick, S. L.; Sahasrabudhe, S.; Stockwell, B. R. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels Nature 2007, 447, 864-868
163. Guo, W.; Wei, X.; Wu, S.; Wang, L.; Peng, H.; Wang, J.; Fang, B. Antagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species Eur. J. Pharmacol. 2010, 649, 51-58
164. Wei, X.; Guo, W.; Wu, S.; Wang, L.; Huang, P.; Liu, J.; Fang, B. Oxidative stress in NSC-741909-induced apoptosis of cancer cells J. Transl. Med. 2010, 8, 37
165. Guo, W.; Wu, S.; Wang, L.; Wang, R.; Wei, L.; Liu, J.; Fang, B. Interruption of RNA processing machinery by a small compound 1-[(4-chlorophenyl)methyl]-1 H -indole-3-carboxaldehyde (oncrasin-1) Mol. Cancer Ther. 2009, 8, 441-448
166. Guo, W.; Wu, S.; Wang, L.; Wei, X.; Liu, X.; Wang, J.; Lu, Z.; Hollingshead, M.; Fang, B. Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition PLoS One 2011, 6, e28487
167. Liu, X.; Guo, W.; Wu, S.; Wang, L.; Wang, J.; Dai, B.; Kim, E. S.; Heymach, J. V.; Wang, M.; Girard, L.; Minna, J.; Roth, J. A.; Swisher, S. G.; Fang, B. Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells Biochem. Pharmacol. 2012, 83, 1456-1464
168. Jaspers, J. E.; Kersbergen, A.; Boon, U.; Sol, W.; van, D. L.; Zander, S. A.; Drost, R.; Wientjens, E.; Ji, J.; Aly, A.; Doroshow, J. H.; Cranston, A.; Martin, N. M.; Lau, A.; O'Connor, M. J.; Ganesan, S.; Borst, P.; Jonkers, J.; Rottenberg, S. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors Cancer Discovery 2013, 3, 68-81
169. Wei, X.; Guo, W.; Wu, S.; Wang, L.; Lu, Y.; Xu, B.; Liu, J.; Fang, B. Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells J. Biol. Chem. 2009, 284, 16948-16955
170. Wu, S.; Wang, L.; Guo, W.; Liu, X.; Liu, J.; Wei, X.; Fang, B. Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities J. Med. Chem. 2011, 54, 2668-2679